CAJ | 학술논문

Bruton酪氨酸激酶(BTK)是Tec激酶家族的一种非受体酪氨酸激酶,在B细胞受体信号转导中发挥重要作用.BTK已经成为靶向治疗某些B细胞恶性肿瘤的一个新靶点.近年来的研究发现,BTK抑制剂PCI-32765(ibrutinib)能有效治疗慢性淋巴细胞白血病与套细胞淋巴瘤等多种B细胞恶性肿瘤.文章就BTK抑制剂在B细胞恶性肿瘤中的研究进展作一综述.
Bruton락안산격매(BTK)시Tec격매가족적일충비수체락안산격매,재B세포수체신호전도중발휘중요작용.BTK이경성위파향치료모사B세포악성종류적일개신파점.근년래적연구발현,BTK억제제PCI-32765(ibrutinib)능유효치료만성림파세포백혈병여투세포림파류등다충B세포악성종류.문장취BTK억제제재B세포악성종류중적연구진전작일종술.
Bruton tyrosine kinase (BTK) is a non-receptor tyrosine kinase which belongs to the Tec kinase family and plays an important role in B cell receptor signaling.Nowadays,BTK has been a nove] target for treating some B cell malignancies.Recently,some studies have confirmed that BTK inhibitor,PCI-32765 (ibrutinib),can effectively treat chronic lymphocytic leukemia,mantle cell lymphoma and so on.This review will discuss the preclinical and clinical development of this BTK inhibitor in B cell malignancies.